We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's p... Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. Show more
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc...
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting SOUTH SAN FRANCISCO, Calif., April...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0142 | -2.30894308943 | 0.615 | 0.6461 | 0.57 | 79017 | 0.60968385 | CS |
4 | -0.2031 | -25.2643363602 | 0.8039 | 0.8377 | 0.57 | 233772 | 0.66152352 | CS |
12 | -0.2892 | -32.4943820225 | 0.89 | 1.1 | 0.57 | 313504 | 0.85580337 | CS |
26 | -0.0992 | -14.1714285714 | 0.7 | 1.2 | 0.5438 | 372886 | 0.78245966 | CS |
52 | -0.5992 | -49.9333333333 | 1.2 | 1.21 | 0.5388 | 231492 | 0.79752509 | CS |
156 | -27.7692 | -97.8822700035 | 28.37 | 34.31 | 0.5388 | 261950 | 4.17171746 | CS |
260 | -14.1392 | -95.9240162822 | 14.74 | 37.5099 | 0.5388 | 238489 | 5.88064767 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions